Abstract | CONTEXT:
Antidiabetic therapies based on potentiation of incretin action are now widely used; however, understanding of their long-term safety remains incomplete. EVIDENCE ACQUISITION: We searched articles in PubMed for data assessing the safety of incretin-based therapies. EVIDENCE SYNTHESIS: CONCLUSIONS: The available data on incretin action and incidence of cardiovascular events, pancreatitis, or cancer are not yet sufficient or robust enough to permit firm conclusions regarding associations with incretin-based therapies in humans with diabetes. The forthcoming results of long-term cardiovascular safety studies should provide more conclusive information about the safety of GLP-1R agonists and dipeptidyl peptidase-4 inhibitors in diabetic patients.
|
Authors | Daniel J Drucker, Steven I Sherman, Richard M Bergenstal, John B Buse |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 96
Issue 7
Pg. 2027-31
(Jul 2011)
ISSN: 1945-7197 [Electronic] United States |
PMID | 21734003
(Publication Type: Journal Article, Review)
|
Chemical References |
- Dipeptidyl-Peptidase IV Inhibitors
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
|
Topics |
- Diabetes Mellitus, Type 2
(drug therapy)
- Dipeptidyl-Peptidase IV Inhibitors
(adverse effects, therapeutic use)
- Glucagon-Like Peptide 1
(adverse effects, therapeutic use)
- Humans
- Hypoglycemic Agents
(adverse effects, therapeutic use)
|